# Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes

> **NCT04657939** · PHASE4 · COMPLETED · sponsor: **University of Leeds** · enrollment: 57 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Liraglutide
- **DRUG:** Pioglitazone

## Key facts

- **NCT ID:** NCT04657939
- **Lead sponsor:** University of Leeds
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-01
- **Primary completion:** 2022-10-31
- **Final completion:** 2022-10-31
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2023-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04657939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04657939, "Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT04657939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*